JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, announced today that data from pre-clinical trials of BL-2030 were presented at the Inflammation-Induced Cancer meeting 2007 held in Jerusalem and the Western Galilee, Israel, on December 16-19, 2007. The data demonstrate that BL-2030, a soluble CCR2 receptor for the treatment of prostate cancer, was effective in significantly reducing tumor growth and preventing metastasis to the lungs and bones of treated mice. Professor Nathan Karin from the Faculty of Medicine at the Technion, Israel Institute of Technology, presented the findings.
